DOCSLIB.ORG

Poorly Differentiated Than Those That Were Negative”

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poorly Differentiated Than Those That Were Negative” 1/10/2016 HPV-Related Oropharyngeal Carcinoma - “Catch Me If You Can!” James S. Lewis Jr. MD Associate Professor Vanderbilt University Medical Center March 16, 2016 Disclosures I have no financial or other conflicts of interest to report. (just that I think way too much about this topic!) 1 1/10/2016 THE “STORY” HPV “Epidemic” in Oropharyngeal SCC - OPSCC incidence up in most countries, particularly in economically more developed ones: - US, UK, Japan, NorthernHPV + Europe, Brazil, but not Asia or South/Central AmericaOropharynx HPV ‐ only - In US, 225% increase in HPV+ oropharyngeal SCC (1984-2004) - 50% decrease in HPV- over same time period *Chaturvedi et al. J Clin Oncol 2012; 29: 4294. *Chaturvedi et al. J Clin Oncol 2013; 31: 4550. 2 1/10/2016 HPV “Epidemic” in Oropharyngeal SCC By 2020, overall oropharyngeal SCC burden in US predictedHPV + to surpass cervical SCC Already Happened!!! ~13,000 patients with OPSCC in 2012* *Chaturvedi et al. J Clin Oncol 2012; 29: 4294. *Chaturvedi et al. J Clin Oncol 2013; 31: 4550. Transmission of HPV • HPV is sexually transmitted • Increased sex partners and practicing oral sex is associated with: – Prevalent and incident oral high risk HPV detection – Increased rates of HPV-related OPSCC • Oral high risk HPV is 1-10% and usually cleared, but can persist – Increased rates and persistence in men and smokers • Risk of HPV from open mouthed kissing suggested Fakry/D’Souza –Oral Oncol 2013; 49(9): 863‐71 3 1/10/2016 Epidemic!!! Well, at least a modest one, anyway… Typical Patient with HPV-Related Oropharyngeal SCC – Caucasian Insert Head – Male (~95%) Shot of Aging Hollywood – 50-60’s Actor Here… – History of smoking (mostly light or former) – Higher than average sex history, particularly oral sex, many partners 4 1/10/2016 Survival Data by p16/HPV Status The Presence of Transcriptionally- Active HPV in Oropharyngeal SCC is Highly and Independently Predictive of Better Patient Survival (patients have ~2-5 times lower risk for overall and disease specific mortality) 5 1/10/2016 Transcriptionally-active HPV-related OPSCC is a clinically, biologically, morphologically, and molecularly distinct form of head and neck SCC SCC Variant Given the prognostic (and emerging treatment) differences, it is critical for us to diagnose them correctly and communicate the findings clearly in our reports All patients with newly diagnosed oropharyngeal squamous cell carcinoma should get some form of p16 +/- HPV testing 6 1/10/2016 Testing should also be performed on: 1) Tissue (and/or FNA cell blocks) from neck metastases of known oropharyngeal primary 2) Tissue (and/or FNA cell blocks) from neck metastases of unknown primary HPV DNA PCR DNA ISH p16 IHC Nonkeratinizing Morphology HPV E6/E7 mRNA ISH 7 1/10/2016 In the oropharynx, all HPV specific and surrogate marker tests shown to be roughly equivalent prognostic markers… So which one(s) to use and what “approach”? Strategies for p16/HPV Testing in Oropharyngeal SCC: Three “Schools” of Thought: 1) p16 immunohistochemistry alone 2) Morphology-informed strategy: nonkeratinizing SCC with + p16 IHC sufficient; all others also get HPV-specific testing 3) Across the board p16 IHC and HPV-specific testing 8 1/10/2016 Expert Opinions/Recommendations College of American Pathologists Cancer Committee Pharynx: Checklist item for p16 IHC (with suggestions for when to add HPV specific testing) p16 p16 HPV Why p16? Sign here _________ p16 overexpression indicates that the HPV is causing “favorable” signaling in the tumor cells 9 1/10/2016 p16 “The Practical Thing” Reproducible p16 Immunohistochemistry Alone Many caveats! (you should know what these are for your practice) 10 1/10/2016 Caveats for p16 IHC Alone • 1) Only in oropharyngeal carcinomas • 2) Extensive nuclear+cytoplasmic staining cutoff (>70%) for calling positivity • 3) Strict rules on use in neck metastases and CUP – (Level II-III and nonkeratinizing morphology) Which p16 Antibody? Which HPV-Specific Test? • No current data supporting one p16 antibody/clone/platform over another* (*but see USCAP abstract ___) • No current data dictating one HPV-specific test over another, either*. *But HPV RNA ISH probably emerging… 11 1/10/2016 Systematic Literature Review CAP Pathology and Laboratory Quality Center: Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinomas Expert Panel HPV-Related Oropharyngeal Carcinoma = The Bad Guy HPV-Related Oropharyngeal Carcinomas Have Many Morphologies and Presentations = Masquerading as Other Lesions 12 1/10/2016 Pathologists = “Tissue Detectives” A Pathologist’s Job? To Recognize “The Bad Guy” in All His Many Forms and to Call Them Out 13 1/10/2016 Today’s Aim: TeachYou Many of the “Faces” of HPV-Related Oropharyngeal Carcinoma Case #1: 57 year old man with dysphagia and a granular and ill-defined mass in the right base of tongue. 14 1/10/2016 Reverse Maturation 15 1/10/2016 Retraction Artifact Brisk Mitotic Activity 16 1/10/2016 p16 Positive Diagnosis: Oropharynx, base of tongue, biopsy: - p16 Positive (or HPV-Related) Squamous Cell Carcinoma, NonkeratinizingType with Maturation 17 1/10/2016 Is this tumor: Well-Differentiated Moderately-Differentiated Poorly-Differentiated Differentiation Not Applicable Answer: Differentiation Not Applicable 18 1/10/2016 Morphology in Oropharyngeal Squamous Cell Carcinoma 19 1/10/2016 20 1/10/2016 “Reverse Keratinizing Areas Maturation” Nonkeratinizing Areas Clefting/Retraction 21 1/10/2016 20‐25% 20‐25% 50‐60% Keratinizing Nonkeratinizing Nonkeratinizing w/Maturation (100% maturing (>10 but <100% (<10% maturing squamous maturing squamous squamous differentiation) differentiation) differentiation) 22 1/10/2016 Nonkeratinizing Morphology and HPV • Four Years of Clinical Practice –Washington University – 435 OPSCC Cases • Nonkeratinizing (NK) SCC = 53% of total cases • 99.1% were p16 positive (226/228) • Combine surrogate markers: • All 48 NKSCC that were “audited” for HPV mRNA (by RTPCR and RNA ISH) were positive (100%) Dibe‐Gondim et al, USCAP Meeting Abstract ‐ 2015 Strictly defined nonkeratinizing SCC (minimal maturing squamous differentiation) is almost implicitly related to transcriptionally-active high risk HPV Chernock. Head Neck Pathol 2009; 3: 186. Lewis Jr. Histopathol 2012; 60: 427. 23 1/10/2016 College of American Pathologists Cancer Committee Pharynx: Protocol for the Examination of Specimens From Patients With Carcinomas of the Pharynx 2013 Modification: p16 IHC sufficient alone for “nonkeratinizing or predominantly nonkeratinizing oropharyngeal SCC” 24 1/10/2016 “Grading” of Oropharyngeal Squamous Cell Carcinoma Literature Descriptions “Patients with HPV positive tumors had a higher prevalence of high grade lesions” “The HPV positive cases were more likely to be poorly differentiated than those that were negative” 25 1/10/2016 Morphology in Oroph SCC • Turns out that “poorly differentiated/high grade” tumors actually have much better prognosis – Nonkeratinizing, partially keratinizing, lymphoepithelial, and basaloid tumors consistently related to transcriptionally-active high risk HPV – Genetically less complex and better treatment response – Paradoxical – and not at all what is clinically conveyed by the terms Let’s come back to the crypts… Nonkeratinizing SCC 26 1/10/2016 *Avoid terms about grading and/or differentiation for p16/HPV positive tumors Fight that urge!!! Now Something Even More Confusing!!! 27 1/10/2016 Nonkeratinizing SCC with Multinucleation Nonkeratinizing SCC with maturation and nuclear anaplasia 28 1/10/2016 Nonkeratinizing SCC with multinucleation and anaplasia Nonkeratinizing SCC with Nuclear Anaplasia p16 29 1/10/2016 p16 Positive Patients vs p16 Negative p16 positive & A/MN negative p16 positive & A/MN positive p16 negative Overall Survival (years) Lewis Jr. et al. Am J Surg Pathol 2012; 36: 1036 Anaplasia and Multinucleation: Only one study to date Only surgically-resected patients Pathologist reproducibility in classification? 30 1/10/2016 Case #1 p16 Positive/HPV-Related OPSCC Mimicking a Poorly Differentiated Tumor Case #2: 42 year old man with a large neck mass. On clinical examination, he has a subtle irregularity of the left tonsil. 31 1/10/2016 p16 Copyright © 2013 by ASCP 63 Diagnosis? 32 1/10/2016 Concept of Tonsillar ‘Crypt Dysplasia’ • Theoretical as precursor lesion • Electron microscopy studies of normal tonsil – “reticulated” crypt epithelium Normal Tonsillar Crypts Copyright © 2013 by ASCP 66 33 1/10/2016 C Normal Tonsillar Crypts L E Capillaries within reticulated crypt epithelium Discontinuous Basement C Membrane E Perry ME. J Anat 1994; 185: 111 What percentage of patients with HPV-related oropharyngeal SCC have nodal metastases at presentation? 20% 35% 50% 80% 95% 34 1/10/2016 Answer: 80% Nodal metastases are present at presentation in ~80 to 85%+ of all HPV-related oropharyngeal squamous cell carcinomas Ang et al. NEJM 2010; 363: 24. Jordan et al. Am J Surg Pathol 2012; 36: 945. Lewis Jr. et al. Am J Surg Pathol 2010: 1044:38. 35 1/10/2016 Tonsillar Crypt Epithelium a Poor Barrier to the Spread of Carcinoma NKSCC Along Tonsillar Crypts Mimicking In Situ Only 36 1/10/2016 Overtly invasive foci also lacking stromal reaction “The tissue doesn’t lie…but it may try to deceive you!” Louis “Pepper” Dehner, MD Washington University in St. Louis http://news.wustl.edu/news/Pages/13804.aspx 37 1/10/2016 Recommended Diagnosis p16 positive (or HPV-related) squamous cell carcinoma, nonkeratinizing type* *No morphologic difference from clearly metastasis-capable tumor *Caveats • Tonsillar
Load more

Recommended publications
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Morphologic Diversity in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: Catch Me If You Can! James S Lewis Jr
    Modern Pathology (2017) 30, S44–S53 S44 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 Morphologic diversity in human papillomavirus-related oropharyngeal squamous cell carcinoma: Catch Me If You Can! James S Lewis Jr Department of Pathology, Microbiology, and Immunology; Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, TN, USA As the human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma epidemic has developed in the past several decades, it has become clear that these tumors have a wide variety of morphologic tumor types and features. For the practicing pathologist, it is critical to have a working knowledge about these in order to make the correct diagnosis, not to confuse them with other lesions, and to counsel clinicians and patients on their significance (or lack of significance) for treatment and outcomes. In particular, there are a number of pitfalls and peculiarities regarding HPV-related tumors and their nodal metastases that can easily result in misclassification and confusion. This article will discuss the various morphologic types and features of HPV- related oropharyngeal carcinomas, specific differential diagnoses when challenging, and, if established, the clinical significance of each finding. Modern Pathology (2017) 30, S44–S53; doi:10.1038/modpathol.2016.152 It is now well-established that human papilloma- Among its many effects on clinical practice, the virus (HPV) is responsible for a large fraction of oropharyngeal HPV epidemic has put pathologists at oropharyngeal squamous cell carcinomas (SCC), the forefront of diagnosis and recognition of these particularly in the United States and Europe.1 Many unique tumors, which are much less clinically have termed the increase in HPV-related orophar- aggressive than conventional head and neck SCC, 7 yngeal SCC as an epidemic.2,3 There are numerous and which are beginning to be managed differently.
    [Show full text]
  • Rare Pancreatic Tumors
    Published online: 2020-04-29 THIEME 64 ReviewRare Pancreatic Article Tumors Choudhari et al. Rare Pancreatic Tumors Amitkumar Choudhari1,2 Pooja Kembhavi1,2 Mukta Ramadwar3,4 Aparna Katdare1,2 Vasundhara Smriti1,2 Akshay D. Baheti1,2 1Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Address for correspondence Akshay D. Baheti, MD, Department of Maharashtra, India Radiodiagnosis, Tata Memorial Hospital, Ernest , Borges Marg Parel 2Department of Radiodiagnosis, Homi Bhabha National University, Mumbai 400012, India (e-mail: [email protected]). Mumbai, Maharashtra, India 3Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India 4Department of Pathology, Homi Bhabha National University, Mumbai, Maharashtra, India J Gastrointestinal Abdominal Radiol ISGAR 2020;3:64–74 Abstract Pancreatic ductal adenocarcinoma, neuroendocrine tumor, and cystic pancreatic neo- plasms are the common pancreatic tumors most radiologists are familiar with. In this Keywords article we review the clinical presentation, pathophysiology, and radiology of rare pan- ► pancreatic cancer creatic neoplasms. While the imaging features are usually nonspecific and diagnosis is ► uncommon based on pathology, the radiology along with patient demographics, history, and lab- ► pancreatoblastoma oratory parameters can often help indicate the diagnosis of an uncommon pancreatic ► acinar cell neoplasm and guide appropriate management in these cases. ► lymphoma Introduction hyperlipasemia may rarely lead to extraabdominal manifes- tations like ectopic subcutaneous fat necrosis and polyarthri- Pancreatic tumors of various histological subtypes can be tis (lipase hypersecretion syndrome).4 encountered in clinical practice, most common being pan- These tumors are hypoenhancing compared with the pan- creatic ductal adenocarcinoma (PDAC), which constitutes creas and are frequently associated with cystic or necrotic 85% of all pancreatic neoplasms.1 Histologically pancreat- areas as well as calcifications5,6 (►Fig.
    [Show full text]
  • 1 Effective January 1, 2018 ICD‐O‐3 Codes, Behaviors and Terms Are Site‐Specific Alpha Order Last Updat
    Effective January 1, 2018 ICD‐O‐3 codes, behaviors and terms are site‐specific Alpha Order Last updated 8/22/18 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code New Term 8551/3 Acinar adenocarcinoma (C34. _) Y Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3 New Term 8140/3 Acinar adenocarcinoma (C61.9 ONLY) Y For prostate only, do not use 8550/3 New Term 8572/3 Acinar adenocarcinoma, sarcomatoid (C61.9) Y New Term 8550/3 Acinar cell carcinoma Y Excludes C61.9‐ see 8140/3 New Term 8316/3 Acquired cystic disease‐associated renal cell carcinoma (RCC) Y (C64.9) New 8158/1 ACTH‐producing tumor N code/term New Term 8574/3 Adenocarcinoma admixed with neuroendocrine carcinoma (C53. _) Y Behavior 8253/2 Adenocarcinoma in situ, mucinous (C34. _) Y Important note: lung Code/term primaries ONLY: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for in‐ situ adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 1 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code Behavior 8250/2 Adenocarcinoma in situ, non‐mucinous (C34. _) Y code/term New Term 9110/3 Adenocarcinoma of rete ovarii (C56.9) Y New 8163/3 Adenocarcinoma, pancreatobiliary‐type (C24.1) Y Cases diagnosed prior to code/term 1/1/2018 use code 8255/3 Behavior 8983/3 Adenomyoepithelioma with carcinoma (C50. _) Y Code/term New Term 8620/3 Adult granulosa cell tumor (C56.9 ONLY) N Not reportable for 2018 cases New Term 9401/3 Anaplastic astrocytoma, IDH‐mutant (C71.
    [Show full text]
  • MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002
    MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002 Michigan Department of Community Health Community Public Health Agency and Center for Health Statistics 3423 N. Martin Luther King Jr. Blvd. P. O. Box 30691 Lansing, Michigan 48909 Michigan Department of Community Health James K. Haveman, Jr., Director B-274a (March, 2002) Authority: P.A. 236 of 1988 BIRTH DEFECTS REGISTRY MICHIGAN DEPARTMENT OF COMMUNITY HEALTH BIRTH DEFECTS REGISTRY STAFF The Michigan Birth Defects Registry staff prepared this manual to provide the information needed to submit reports. The manual contains copies of the legislation mandating the Registry, the Rules for reporting birth defects, information about reportable and non reportable birth defects, and methods of reporting. Changes in the manual will be sent to each hospital contact to assist in complete and accurate reporting. We are interested in your comments about the manual and any suggestions about information you would like to receive. The Michigan Birth Defects Registry is located in the Office of the State Registrar and Division of Health Statistics. Registry staff can be reached at the following address: Michigan Birth Defects Registry 3423 N. Martin Luther King Jr. Blvd. P.O. Box 30691 Lansing MI 48909 Telephone number (517) 335-8678 FAX (517) 335-9513 FOR ASSISTANCE WITH SPECIFIC QUESTIONS PLEASE CONTACT Glenn E. Copeland (517) 335-8677 Cytogenetics Laboratory Reporting Instructions I. INTRODUCTION This manual provides detailed instructions on the proper reporting of diagnosed birth defects by cytogenetics laboratories. A report is required from cytogenetics laboratories whenever a reportable condition is diagnosed for patients under the age of two years.
    [Show full text]
  • Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes Lymphoma and Leukemia M9590-9989 and Kaposi Sarcoma M9140)
    Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations C340-C349 (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140) Introduction Use these rules only for cases with primary lung cancer. Lung carcinomas may be broadly grouped into two categories, small cell and non-small cell carcinoma. Frequently a patient may have two or more tumors in one lung and may have one or more tumors in the contralateral lung. The physician may biopsy only one of the tumors. Code the case as a single primary (See Rule M1, Note 2) unless one of the tumors is proven to be a different histology. It is irrelevant whether the other tumors are identified as cancer, primary tumors, or metastases. Equivalent or Equal Terms • Low grade neuroendocrine carcinoma, carcinoid • Tumor, mass, lesion, neoplasm (for multiple primary and histology coding rules only) • Type, subtype, predominantly, with features of, major, or with ___differentiation Obsolete Terms for Small Cell Carcinoma (Terms that are no longer recognized) • Intermediate cell carcinoma (8044) • Mixed small cell/large cell carcinoma (8045) (Code is still used; however current accepted terminology is combined small cell carcinoma) • Oat cell carcinoma (8042) • Small cell anaplastic carcinoma (No ICD-O-3 code) • Undifferentiated small cell carcinoma (No ICD-O-3 code) Definitions Adenocarcinoma with mixed subtypes (8255): A mixture of two or more of the subtypes of adenocarcinoma such as acinar, papillary, bronchoalveolar, or solid with mucin formation. Adenosquamous carcinoma (8560): A single histology in a single tumor composed of both squamous cell carcinoma and adenocarcinoma. Bilateral lung cancer: This phrase simply means that there is at least one malignancy in the right lung and at least one malignancy in the left lung.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Rare Epithelial Tumours of the Thoracic Cavity 3 590 9
    RARE EPITHELIAL TUMOURS OF THE 8% OF ALL TUMOURS OF THE THORACIC THORACIC CAVITY CAVITY ARE RARE EPITHELIAL TUMOURS EPITHELIAL TUMOURS 113 OF TRACHEA 95 % OF RARE EPITHELIAL INCIDENCE TUMOURS 1 699 RARE EPITHELIAL TUMOURS 4 OUT OF ALL TUMOURS OF LUNG IN EACH SITE 3 590 EPITHELIAL TUMOURS 232 97 ESTIMATED NEW CASES OF THYMUS ITALY, 2015 MESOTHELIOMA OF PLEURA 1 546 AND PERICARDIUM 74 PREVALENCE 9 933 ESTIMATED PREVALENT CASES ITALY, 2010 SURVIVAL 100% 50% 17% 0 1 5 YEARS AFTER DIAGNOSIS SOURCE: AIRTUM. ITALIAN CANCER FIGURES–REPORT 2015 RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY I tumori in Italia • Rapporto AIRTUM 2015 INCIDENCE RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in Italy. AIRTUM POOL (period of diagnosis 2000-2010) ITALY SEX AGE MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs ESTIMATED NEW CASES RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI 2015 OBSERVED CASES OBSERVED (No.) CANCERS RARE (%) SITE BY RARE EPITHELIAL TUMOURS 5.42 5.33-5.52 12 027 8% 8.57 8.39-8.74 2.48 2.39-2.57 0.87 0.82-0.92 10.14 9.77-10.53 18.08 17.69-18.49 3 590 OF THE THORACIC CAVITY EPITHELIAL TUMOURS OF TRACHEA 0.17 0.15-0.19 374 95% 0.27 0.24-0.30 0.07 0.06-0.09 0.03 0.02-0.04 0.33 0.27-0.41 0.55 0.48-0.62 113 Squamous cell carcinoma with variants of trachea 0.08 0.07-0.09 175 0.14 0.11-0.16 0.03 0.02-0.04
    [Show full text]
  • Primary Adenosquamous Cell Carcinoma of the Ileum in a Dog
    veterinary sciences Case Report Primary Adenosquamous Cell Carcinoma of the Ileum in a Dog Masashi Yuki 1,* , Roka Shimada 1 and Tetsuo Omachi 2 1 Yuki Animal Hospital, 2-99 kiba-cho, Minato-ku, Nagoya, Aichi 455-0021, Japan; [email protected] 2 Patho Labo, 9-400 Oomurokougen, Ito, Shizuoka 413-0235, Japan; [email protected] * Correspondence: [email protected] Received: 18 September 2020; Accepted: 13 October 2020; Published: 14 October 2020 Abstract: A 9-year-old male, castrated Chihuahua was examined because of a 7-day history of intermittent vomiting. A mass in the small intestine was identified on abdominal radiography and ultrasonography. Laparotomy revealed a mass lesion originating in the ileum, and surgical resection was performed. The mass was histologically diagnosed as adenosquamous cell carcinoma. Chemotherapy with carboplatin was initiated, but the dog was suspected to have experienced recurrence 13 months after surgery and died 3 months later. To our knowledge, this is the first case report to describe the clinical course of adenosquamous cell carcinoma in the small intestine of a dog. Keywords: adenosquamous cell carcinoma; dog; ileum 1. Introduction Lymphoma is the most common type of intestinal tumor in dogs, followed by adenocarcinoma, leiomyosarcoma, and gastrointestinal stromal tumor [1]. Adenosquamous cell carcinoma (ASCC) is defined as a malignant tumor with glandular and squamous components and metastatic potential [2]. ASCC of the gastrointestinal tract is extremely rare in dogs, having been previously reported only in the esophagus and colorectal region [3,4]. ASCC of the small intestine is extremely uncommon in humans, with only nine cases having been reported to date [5].
    [Show full text]
  • Dermatopathology
    Dermatopathology Clay Cockerell • Martin C. Mihm Jr. • Brian J. Hall Cary Chisholm • Chad Jessup • Margaret Merola With contributions from: Jerad M. Gardner • Talley Whang Dermatopathology Clinicopathological Correlations Clay Cockerell Cary Chisholm Department of Dermatology Department of Pathology and Dermatopathology University of Texas Southwestern Medical Center Central Texas Pathology Laboratory Dallas , TX Waco , TX USA USA Martin C. Mihm Jr. Chad Jessup Department of Dermatology Department of Dermatology Brigham and Women’s Hospital Tufts Medical Center Boston , MA Boston , MA USA USA Brian J. Hall Margaret Merola Department of Dermatology Department of Pathology University of Texas Southwestern Medical Center Brigham and Women’s Hospital Dallas , TX Boston , MA USA USA With contributions from: Jerad M. Gardner Talley Whang Department of Pathology and Dermatology Harvard Vanguard Medical Associates University of Arkansas for Medical Sciences Boston, MA Little Rock, AR USA USA ISBN 978-1-4471-5447-1 ISBN 978-1-4471-5448-8 (eBook) DOI 10.1007/978-1-4471-5448-8 Springer London Heidelberg New York Dordrecht Library of Congress Control Number: 2013956345 © Springer-Verlag London 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
    [Show full text]
  • I ABSTRACTS I BARD Cosmaan, M.D., EDITOR NATIONAL COMMITTEE Oscar E. Beder, D.D.S. Andrew Blitzer, M.D. Robert M. Briggs, M.D. W
    I ABSTRACTS I BARD CosmaAN, M.D., EDITOR NATIONAL COMMITTEE Oscar E. Beder, D.D.S. Stephen Glaser, M.D. Norman J. Lass, Ph.D. Andrew Blitzer, M.D. Alexander Goldenberg, D.D.S. Dennis O. Overman, Ph.D. Robert M. Briggs, M.D. John B. Gregg, M.D. Dennis M. Ruscello, Ph.D. William Cooper, M.D. Jerry Alan Greene, D.V.M. F. T. Sporck, M.D. Jack C. Fisher, M.D. Daubert Telsey, D.D.S. INTERNATIONAL COMMITTEE Paul Fogh-Andersen, M.D., Copenhagen, Denmark Seiichi Ohmori, M.D., Tokyo, Japan Jean L. Grignon, M.D., Nevilly, France Anthony D. Pelly, M.D., Sydney, Australia Jose Guerrero-Santos, M.D., Guadalajara City, Helen Peskova, M.D., Prague, Czechoslovakia Mexico H. Reichert, M.D., Stuttgart, West Germany Stewart B. Heddle, M.D., Ontario, Canada W. H. Reid, M.D., Glasgow, Scotland Junji Machida, D.D.S., Shiojiri City, Japan E. Schmid, M.D., Stuttgart, West Germany Francesco Minnervini, M.D., Rome, Italy Jean Claude Talmant, M.D., Nantes, France Beninceton, I. C., and C1irroRrp, T., An injec- the inconveniences. A great deal of patience tion technique for palatal defects, ]. is required to properly communicate with Prosth. Dent., 47: 414-418, 1982. these patients. (Goldenberg) To further retention of prosthetic devices obturating palatal defects, advantage is taken FuKupa, T., Goto, T., Wapa, T., and Mrya- of undercuts, Extension of borders are made ZAKI, T'., Maternal mentality for the chil- with flexible arms into the undercuts without dren with clefts, /J. Jap. Cleft Palate Assoc., undue impingement, and the prosthesis can 6(2): 55-62, 1981.
    [Show full text]
  • Adenosquamous Carcinoma of the Pancreas: a Case Report
    Medical Research Archives 2015 Issue 3 ADENOSQUAMOUS CARCINOMA OF THE PANCREAS: A CASE REPORT Keisha Brooks, MS, CT(ASCP)MB University of Tennessee Health Science Center [email protected] David W. Mensi, BS, SCT(ASCP) Trumbull Laboratory [email protected] There are no institutional, personal, or financial conflicts of interest associated with this submission. Abstract: Adenosquamous carcinoma of the pancreas is a rare and aggressive variant of ductal adenocarcinoma which presents both glandular and squamous morphologic features. A cytologic diagnosis of adenosquamous carcinoma on fine needle aspirate preparations is dependent on the identification of both malignant glandular and squamous components. Diagnosis of the malignancy is not particularly difficult if both glandular and squamous components are abundant; however, diagnostic challenges may occur when there is scant cellularity of one of the components, or if one of the components is absent. Because a primary squamous carcinoma of the pancreas is non-existent, a careful search and identification of glandular malignant cells is essential in cases that are squamous dominant. In this report a case of adenosquamous carcinoma is presented in which a fine needle aspirate was performed. The cytologic and histologic features are described. The cytology findings showed a two cell population of malignant squamous and glandular cells. The histologic findings also showed both glandular and squamous malignant cells, thus confirming the diagnosis of adenosquamous carcinoma. Keywords: Pancreas, Adenosquamous Carcinoma, Mucoepidermoid Carcinoma, Andenoacanthoma Copyright © 2015, Knowledge Enterprises Incorporated. All rights reserved. 1 Medical Research Archives 2015 Issue 3 1. CASE REPORT 2. CYTOLOGIC FINDINGS The patient is a 41 year old African The FNA produced a cellular American male with no family history of specimen consisting of a two cell pancreatic cancer.
    [Show full text]